Menu

Back to Medication Guide

Risedronate

Generic Name: Risedronate Sodium

Brand Names: Actonel, Atelvia

Risedronate is an oral bisphosphonate for osteoporosis and Paget's disease, available in daily, weekly, or monthly dosing.

EndocrineBone Health

Drug Class

Bisphosphonate (Nitrogen-Containing, Pyridinyl)

Pregnancy

Category C; no adequate studies in pregnant women. Animal studies showed decreased survival and body weight of neonates at doses producing maternal hypocalcemia. Should not be used during pregnancy due to potential risk to the developing skeleton.

Available Forms

5 mg oral tablet (daily), 30 mg oral tablet (for Paget disease), 35 mg oral tablet (weekly), 35 mg delayed-release tablet (Atelvia, weekly, taken after breakfast), 150 mg oral tablet (monthly)

Dosage Quick Reference

These are general dosage guidelines. Your doctor will determine the appropriate dose for your specific situation.

ConditionStarting DoseMaintenance Dose
Postmenopausal Osteoporosis (treatment/prevention)5 mg daily, 35 mg weekly, or 150 mg monthlySame; reassess need after 3-5 years
Glucocorticoid-Induced Osteoporosis5 mg daily5 mg daily for the duration of glucocorticoid treatment
Paget Disease of Bone30 mg daily for 2 monthsRe-treatment may be considered after at least 2-month post-treatment observation if relapse occurs

Side Effects

Common Side Effects:

  • Abdominal pain
  • Dyspepsia
  • Nausea
  • Diarrhea
  • Constipation
  • Headache
  • Arthralgia

Serious Side Effects:

  • Esophageal ulcers/erosions
  • Osteonecrosis of the jaw
  • Atypical femur fractures
  • Severe musculoskeletal pain
  • Hypocalcemia

Drug Interactions

  • Calcium supplements, antacids, and mineral supplements (calcium, magnesium, iron, aluminum): These polyvalent cations significantly reduce risedronate absorption. Take risedronate at least 30 minutes before (or at a different time than) calcium or antacid products.
  • Proton pump inhibitors (omeprazole, pantoprazole): Long-term PPI use may reduce calcium absorption and has been independently associated with fracture risk. Combined use with bisphosphonates may warrant closer bone density monitoring.
  • NSAIDs (ibuprofen, naproxen, aspirin): Both bisphosphonates and NSAIDs can irritate the GI tract. Concurrent use may increase the risk of esophageal erosion, gastric ulcers, or GI bleeding. Use the lowest effective NSAID dose.
  • Aminoglycoside antibiotics (gentamicin): Both agents can lower serum calcium. Monitor calcium levels if concurrent use is necessary.

Additional Information

Risedronate is a nitrogen-containing bisphosphonate used to prevent and treat osteoporosis, Paget's disease of bone, and glucocorticoid-induced osteoporosis. It reduces bone resorption and fracture risk.

Mechanism of Action

Risedronate inhibits osteoclast-mediated bone resorption:

  • Binds to hydroxyapatite: Concentrates at sites of active bone remodeling
  • Inhibits farnesyl pyrophosphate synthase: Key enzyme in the mevalonate pathway
  • Disrupts osteoclast function: Prevents prenylation of small GTPases essential for osteoclast activity
  • Induces osteoclast apoptosis: Leads to reduced bone resorption
  • Improves bone mineral density: Results in decreased fracture risk

Effects persist for months to years after discontinuation due to incorporation into bone matrix.

Available Formulations

  • Immediate-release tablets: 5 mg (daily), 30 mg (Paget's), 35 mg (weekly), 150 mg (monthly)
  • Delayed-release tablets: 35 mg (weekly, taken immediately after breakfast)

Medical Uses

FDA-Approved Indications:

  • Prevention and treatment of postmenopausal osteoporosis
  • Treatment to increase bone mass in men with osteoporosis
  • Prevention and treatment of glucocorticoid-induced osteoporosis
  • Paget's disease of bone

Dosing Guidelines

Postmenopausal Osteoporosis:

  • 5 mg daily, OR
  • 35 mg weekly, OR
  • 150 mg monthly
  • Delayed-release: 35 mg weekly immediately after breakfast

Osteoporosis in Men:

  • 35 mg weekly

Glucocorticoid-Induced Osteoporosis:

  • 5 mg daily

Paget's Disease:

  • 30 mg daily for 2 months
  • Retreatment may be considered after 2-month observation period if needed

Important Safety Information

Contraindications:

  • Hypocalcemia
  • Inability to sit or stand upright for at least 30 minutes
  • Esophageal abnormalities that delay emptying (stricture, achalasia)
  • Known hypersensitivity to risedronate

Warnings and Precautions:

  • Esophageal adverse reactions: Esophagitis, esophageal ulcers, strictures
  • Osteonecrosis of the jaw: Associated with bisphosphonate use
  • Atypical femur fractures: Low-energy subtrochanteric and diaphyseal fractures
  • Severe bone, joint, or muscle pain: May occur at any time during treatment
  • Hypocalcemia: Correct before initiating; supplement with calcium and vitamin D

Drug Interactions

  • Calcium supplements, antacids, oral medications with divalent cations: Impair absorption; separate by at least 30 minutes
  • PPIs, H2 antagonists: May reduce absorption of delayed-release formulation (take with food)
  • NSAIDs: May increase GI adverse effects

Administration Instructions

Immediate-Release:

  • Take first thing in the morning on empty stomach with 6-8 oz plain water
  • Remain upright (sitting or standing) for at least 30 minutes
  • Wait at least 30 minutes before eating, drinking, or taking other medications

Delayed-Release:

  • Take immediately after breakfast with at least 4 oz plain water
  • Remain upright for at least 30 minutes
  • Do not take on an empty stomach

Special Populations

  • Renal Impairment: Not recommended if CrCl <30 mL/min
  • Hepatic Impairment: No adjustment needed
  • Pregnancy: Not recommended
  • Lactation: Not recommended
  • Pediatric: Not approved for children

Frequently Asked Questions

Take the immediate-release tablet first thing in the morning on an empty stomach with a full glass (6-8 oz) of plain water only. Do not eat, drink anything else, or take other medications for at least 30 minutes afterward. Remain upright (sitting or standing) for at least 30 minutes to reduce the risk of esophageal irritation. The delayed-release formulation (Atelvia) is different — it should be taken immediately after breakfast.
Yes. Clinical studies have shown that the weekly 35 mg and monthly 150 mg regimens provide equivalent bone mineral density improvements and fracture risk reduction compared to the daily 5 mg dose. Many patients prefer weekly or monthly dosing for convenience and better adherence.
Most guidelines recommend reassessing after 3 to 5 years of treatment. For patients at moderate risk, a bisphosphonate holiday may be appropriate because the drug remains in bone for years. For patients at high fracture risk, continued treatment beyond 5 years may be recommended. Your doctor will base the decision on your bone density results and fracture history.
Atypical subtrochanteric and diaphyseal femoral fractures have been reported with long-term bisphosphonate use (typically beyond 3-5 years). These are rare but serious. Report any new thigh or groin pain to your doctor immediately, as this can be an early warning sign.

Questions to Ask Your Doctor

Consider discussing these topics at your next appointment:

  • Have my vitamin D levels been checked and optimized before starting risedronate?
  • Should I take the weekly or monthly formulation for better adherence?
  • After how many years should we discuss a bisphosphonate holiday?
  • Do I need a baseline DXA scan, and how often should it be repeated?
  • Should I complete any dental procedures before starting this medication?

Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.